Bladder Cancer – Executive Market Summary 2011

• Publication date: May 2012
• Report size: 16 pages

Abstract TheBladder Cancer Executive Market Summary 2011 provides an overview of the disease and related conditions, with incidence, prevalence, and mortality numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the cancer market, as well as sales of leading drugs and therapies...

Abstract
TheBladder Cancer Executive Market Summary 2011 provides an overview of the disease and related conditions, with incidence, prevalence, and mortality numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the cancer market, as well as sales of leading drugs and therapies are provided.

Additional Details

Executive Market Summaries were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format.  These reports are prepared by the senior market research team of Timely Data Resources.  Each Executive Market Summary provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities.  Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends.  The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Lange's Current Medical Diagnosis and Treatment.  This information is supplemented by reviews of analyst reports, company reports, and medical websites.  Sources and references are provided.  

Pathology Industry in North America

Overview
General description of the condition
Risk factors
Symptoms and signs
incidence, prevalence and mortality
Incidence Table (Canada, US, Argentina, Brazil, Mexico, France, Germany, Greece, Italy, Poland, Russian Federation, Spain, Sweden, Turkey, UK, China, India, Japan, Philippines, Thailand, Egypt, South Africa, Africa, Americas, Eastern Mediterranean, Europe, Southeast Asia, Western Pacific, Worldwide)
Prevalence Table (Canada, US, Mexico, France, Germany, Italy, Spain, UK, China, India, Japan, Worldwide)
Mortality Table (Canada, US, Argentina, Brazil, Mexico, France, Germany, Greece, Italy, Poland, Russian Federation, Spain, Sweden, Turkey, UK, China, India, Japan, Philippines, Thailand, Egypt, South Africa, Africa, Americas, Eastern Mediterranean, Europe, Southeast Asia, Western Pacific, Worldwide)
diagnosis and staging
Diagnostic tests
Classification and staging
treatment
Surgery
Intravesical chemotherapy and immunotherapy
Systemic chemotherapy
Radiotherapy
Interstitial implantation of radioisotopes
Clinical trials
Outcomes by stage
dosing and treatment costs
Overview of costs
Dosing for intravesical therapies
market size
Overall market size
Sales information for key pharmaceuticals
comments
references/resources